Effective oral chemotherapy for breast cancer: pillars of strength.
AffiliationFaculty of Medical & Health Sciences, University of Auckland, Auckland, New Zealand. firstname.lastname@example.org
MetadataShow full item record
AbstractTraditionally, anticancer therapy has been dominated by intravenous drug therapy. However, oral agents provide an attractive approach to chemotherapy and use of oral treatments is increasing. We discuss the benefits and challenges of oral chemotherapy from the perspectives of patients, healthcare providers and healthcare funders. Important issues include patient preference, efficacy, compliance, bioavailability, reimbursement, use in special patient populations, financial and staff time savings and flexibility of dosing. We review data for traditional oral agents (e.g. cyclophosphamide, methotrexate), newer oral chemotherapies (e.g. capecitabine), oral formulations of traditionally intravenous agents (e.g. vinorelbine, idarubicin) and new biologic agents under evaluation in breast cancer (e.g. tyrosine kinase inhibitors). Lastly, we review studies of all-oral combination regimens. The wealth of data available and the increasing use of oral agents in breast cancer suggest that many of the concerns and perceptions about oral therapy, including efficacy and bioavailability, have been overcome, and that oral therapy will play a major role in breast cancer management in the future in both the metastatic and adjuvant settings.
CitationEffective oral chemotherapy for breast cancer: pillars of strength. 2008, 19 (2):212-22 Ann. Oncol.
JournalAnnals of Oncology
- Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial.
- Authors: Leonard RC, Lind M, Twelves C, Coleman R, van Belle S, Wilson C, Ledermann J, Kennedy I, Barrett-Lee P, Perren T, Verrill M, Cameron D, Foster E, Yellowlees A, Crown J, Anglo-Celtic Cooperative Oncology Group.
- Issue date: 2004 Jul 21
- Trends in recommendations of myelosuppressive chemotherapy for the treatment of breast cancer: evolution of the national comprehensive cancer network guidelines and the cooperative group studies.
- Authors: Rivera E, Smith RE Jr
- Issue date: 2006 Apr
- Capecitabine/Taxane combination therapy: evolving clinical utility in breast cancer.
- Authors: O'Shaughnessy JA, Blum JL
- Issue date: 2006 Apr
- Cyclophosphamide-methotrexate 'metronomic' chemotherapy for the palliative treatment of metastatic breast cancer. A comparative pharmacoeconomic evaluation.
- Authors: Bocci G, Tuccori M, Emmenegger U, Liguori V, Falcone A, Kerbel RS, Del Tacca M
- Issue date: 2005 Aug
- Adjuvant use of taxanes for patients with breast cancer: we see the tip of the iceberg.
- Authors: Hudis C
- Issue date: 2002 Dec